Priority in the pharmacological management of chronic schizophrenia: the quality of life issues.
The progress of pharmacological management of schizophrenia is briefly reviewed, highlighting some of the major limitations especially in regard to side-effects which have been identified. The importance of the quality of life issues in chronic patients undergoing pharmacological treatment is stressed. A possible new approach is the use of beta-adrenergic blocking drugs which may have symptomatic effects as well as quality of life effects.
D002908:Chronic Disease; D006801:Humans; D011433:Propranolol / Q000627:therapeutic use*; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*; D011788:Quality of Life; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*
D011619:Psychotropic Drugs; D011433:Propranolol